SILO Stock: Silo Pharma Jumps Into Rheumatoid Arthritis
Silo Pharma, Inc. (OTCQB: SILO) is headed up in the market this morning, and for good reason. The company announced that it entered into an exclusive option agreement surrounding patented homing peptides for the potential treatment of Rheumatoid Arthritis. Here’s what’s happening: Skip to What You Want to Read Silo Pharma Enters Option Agreement Management … Read more